Physician profile
Alan J Iezzi
NPI 1952590028
$4,161.16
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $721 · 2021: $359 · 2022: $585 · 2023: $723 · 2024: $978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,701.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $914.19 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $536.74 | 2019-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $534.63 | 2022-2024 | Mounjaro, Zepbound, Emgality |
| Kowa Pharmaceuticals America, INC. | $490.87 | 2019-2022 | |
| Pfizer INC. | $490.72 | 2020-2024 | |
| Amgen INC. | $197.11 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $138.45 | 2019-2022 | |
| Amarin Pharma, INC. | $136.90 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.45 | 2024 | |
| Abbvie INC. | $86.83 | 2019-2024 | |
| Exact Sciences Corporation | $75.11 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $73.47 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $70.84 | 2022-2024 | Contrave, Nexlizet, Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.40 | 2019-2024 | Xifaxan |
| Esperion Therapeutics, INC. | $42.47 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $30.68 | 2019 | |
| Allergan, INC. | $28.83 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.56 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $24.47 | 2024 | Evkeeza |
| Lucid Diagnostics INC. | $20.09 | 2022 | |
| Dexcom, INC. | $17.91 | 2024 | Dexcom G6 Transmitter |
| Stimwave Technologies Incorporated | $17.77 | 2019 | |
| Optinose US, INC. | $16.82 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.71 | 2020 | |
| Glaxosmithkline, LLC. | $14.14 | 2024 | Shingrix |
| Intuity Medical INC | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Iezzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.